Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,163 matching trials from the live ClinicalTrials.gov search.
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Placebo (for Dupilumab)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
Completed Phase 3 Interventional Results available

Anakinra to Prevent Post-infarction Remodeling

NCT00789724
Conditions
ST Segment Elevation Acute Myocardial Infarction
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for Teriflunomide), Interferon-β
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Polymyositis, Dermatomyositis
Interventions
KZR-616, Placebo
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Beverly Hills, California • Orange, California • Miami, Florida + 9 more
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Conditions
Pain, Neuralgia, Postherpetic, Neuralgia, Mononeuropathies
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Redondo Beach, California + 37 more
Conditions
Polymyalgia Rheumatica
Interventions
Sarilumab SAR153191 (REGN88), Sarilumab-matching placebo, Prednisone, Prednisone-matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Upland, California • Denver, Colorado • Stamford, Connecticut + 7 more
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab, Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
7,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 22 more
Conditions
Psoriatic Arthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 19 more
Conditions
Triple Negative Breast Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
47
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
Conditions
Acute Gout
Interventions
Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
96
States / cities
Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more
Conditions
Primary Sjögren's Syndrome
Interventions
Baminercept, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 6 more
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
60
States / cities
Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more
Enrolling by invitation Phase 2 Interventional

Alzheimer's Tau Platform: Regimen A - AADvac1

NCT07167966
Conditions
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
Interventions
AADvac1, Donanemab
Drug
Lead sponsor
Paul S. Aisen
Other
Eligibility
50 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Phoenix, Arizona • San Francisco, California • Lexington, Kentucky + 4 more
Conditions
Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating, Pain, Splitting
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Laguna Hills, California + 14 more
Completed Not applicable Interventional Results available

The Effect of Omalizumab on Responses to Cat Allergen Challenge

NCT00604786
Conditions
Allergic Rhinitis
Interventions
omalizumab, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

NCT01327495
Conditions
Healthy
Interventions
placebo acyline, placebo gel, Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g, testosterone 1% gel 10 g, testosterone 1% gel 15 g, Acyline
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Angioedema
Interventions
Placebo, Lanadelumab
Other · Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more
Completed Phase 2 Interventional Results available

ACT34-CMI -- Adult Autologous CD34+ Cells

NCT00300053
Conditions
Myocardial Ischemia
Interventions
CLBS14 (low-dose), CLBS14 (high-dose), placebo injection
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Conditions
Traumatic Brain Injury
Interventions
Angiotensin (1-7), Sterile saline
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ohio City, Ohio
Conditions
Obesity/Therapy
Interventions
Semaglutide 1.7mg subcutaneous, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Aurora, Colorado